GRAIL

Today GRAIL reported third quarter 2026 financial results.

Read the press release: bit.ly/3UuTlDq

We will report third quarter 2026 financial results on November 4.

Register for the webcast: bit.ly/4siXcj9
Read more: bit.ly/4k89d94

We’re looking forward to presenting several abstracts at EDCC and #ESMO26 that highlight advances in multi-cancer early detection, spanning clinical performance, health equity, real-world implementation, and the cancer diagnostic journey.

Learn more: bit.ly/4hEXBJn

Today GRAIL announced a favorable vote from an FDA Advisory Committee for the approval of the Premarket Approval application of the Galleri multi-cancer early detection test (MCED).

The Committee considered Galleri’s safety, effectiveness, and overall benefit-risk profile for screening for the early detection of multiple types of cancer in adults aged 50 years and older.

Read more: bit.ly/4rpmwUd

#MCED #Galleri #CancerScreening

Full cohort results from GRAIL’s PATHFINDER 2 study have been published in @NatureMedicine, adding to the growing body of evidence supporting multi-cancer early detection (MCED) testing.

Learn more: bit.ly/4y3psIK

Rx Only. See Important Safety Information: bit.ly/411L6zk